Loading...
OTCM
ADXS
Market cap4mUSD
Dec 05, Last price  
0.10USD
1D
0.00%
1Q
211.11%
Jan 2017
-99.90%
IPO
-99.99%
Name

Ayala Pharmaceuticals Inc

Chart & Performance

D1W1MN
OTCM:ADXS chart
P/E
—
P/S
339.44
EPS
—
Div Yield, %
—
Shrs. gr., 5y
11.87%
Rev. gr., 5y
-70.74%
Revenues
13k
-94.80%
116,406552,868431,961154,20165,73629,690508,4810001,000,00003,994,85612,031,0506,063,0002,334,000253,0003,240,000250,00013,000
Net income
-48m
L+234.79%
-538,076-1,805,789-6,197,744-2,454,453-5,416,418929,244-10,812,200-8,115,740-12,069,687-19,986,826-16,525,314-47,031,118-73,556,230-93,435,402-66,515,000-17,792,000-26,469,000-17,862,000-14,359,000-48,072,000
CFO
-29m
L+92.91%
-436,636-1,539,930-1,795,045-4,234,046-4,153,088-2,034,636-6,423,940-8,942,842-4,568,344-8,713,945-17,021,659-24,135,544-9,070,545-76,923,985-62,129,000-14,950,000-21,940,000-15,439,000-15,284,000-29,485,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey.
URL
https://ayalapharma.com/
IPO date
Jul 28, 2005
Employees
14
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2023‑122022‑102021‑102020‑102019‑102018‑102017‑102016‑10
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT